PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'FaBioCell, Core Facilities, Istituto Superiore di Sanità, viale Regina Elena 299, 00161, Rome, Italy. eleonora.arico@iss.it.\', \'FaBioCell, Core Facilities, Istituto Superiore di Sanità, viale Regina Elena 299, 00161, Rome, Italy.\', \'Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, viale Regina Elena 299, 00161, Rome, Italy.\', \'Medical Biotechnology and Translational Medicine PhD School, II University of Rome \'Tor Vergata\', Via Montpellier 1, 00133, Rome, Italy.\', \'National Centre for Disease Prevention and Health Promotion, Istituto Superiore di Sanità, viale Regina Elena 299, 00161, Rome, Italy.\', \'Special Units for Regional Continued Care (USCAR), Rome, Italy.\', \'Institute of Translational Pharmacology, National Research Council, Via Fosso del Cavaliere 100, 00133, Rome, Italy.\', \'National Institute for Infectious Diseases \'Lazzaro Spallanzani\', Via Portuense 292, 00149, Rome, Italy.\', \'Institute of Translational Pharmacology, National Research Council, Via Fosso del Cavaliere 100, 00133, Rome, Italy. filippo.belardelli@ift.cnr.it.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1186/s13063-021-05367-6
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 34479601
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all